Serum sphingolipids predict de novo hepatocellular carcinoma in hepatitis C cirrhotic patients with sustained virologic response

2019 ◽  
Vol 39 (11) ◽  
pp. 2174-2183 ◽  
Author(s):  
Victoria T. Mücke ◽  
Dominique Thomas ◽  
Marcus M. Mücke ◽  
Oliver Waidmann ◽  
Stefan Zeuzem ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C ◽  
Sustained Virologic Response ◽  
De Novo ◽  
Virologic Response ◽  
Cirrhotic Patients ◽  
De Novo Hepatocellular Carcinoma

scholarly journals Characteristics and Prognosis of De Novo Hepatocellular Carcinoma After Sustained Virologic Response

2021 ◽  
Author(s):  
Hidenori Toyoda ◽  
Atsushi Hiraoka ◽  
Haruki Uojima ◽  
Akito Nozaki ◽  
Noritomo Shimada ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Sustained Virologic Response ◽  
De Novo ◽  
Virologic Response ◽  
De Novo Hepatocellular Carcinoma

scholarly journals Impact of COVID‐19 pandemic on surveillance of hepatocellular carcinoma: A study in patients with chronic hepatitis C after sustained virologic response

GastroHep ◽  
2020 ◽  
Vol 2 (5) ◽  
pp. 247-252
Author(s):  
Hidenori Toyoda ◽  
Satoshi Yasuda ◽  
Seiki Kiriyama ◽  
Makoto Tanikawa ◽  
Yasuhiro Hisanaga ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Sustained Virologic Response ◽  
Virologic Response

Dynamic Evaluation of Liver Fibrosis to Assess the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis C Who Achieved Sustained Virologic Response

2019 ◽  
Author(s):  
Hidenori Toyoda ◽  
Toshifumi Tada ◽  
Satoshi Yasuda ◽  
Kazuyuki Mizuno ◽  
Takanori Ito ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C ◽  
Liver Fibrosis ◽  
Sustained Virologic Response ◽  
Dynamic Assessment ◽  
Predictive Ability ◽  
Virologic Response ◽  
Hcv Therapy ◽  
Number Of Patients ◽  
Advanced Liver Fibrosis

Abstract Background Liver fibrosis is an important risk factor for the development of hepatocellular carcinoma (HCC) after sustained virologic response (SVR) in patients with persistent hepatitis C virus (HCV) infection. However, as the degree of liver fibrosis changes following the eradication of HCV after SVR, it is unclear whether the prediction of HCC development based on liver fibrosis at baseline remains valid. Methods In 522 patients who achieved SVR by interferon-based anti-HCV therapy, the Fibrosis-4 Index for Liver Fibrosis (FIB-4 index) was updated annually by recalculation based on laboratory values after SVR. The incidence of HCC was reassessed annually based on the updated FIB-4 index. Results The percentage of patients with mild liver fibrosis (FIB-4 index <1.45) increased annually after SVR, whereas the percentage of patients with advanced liver fibrosis (FIB-4 index ≥3.25) decreased. The incidences of HCC based on the FIB-4 index remained constant between the time of SVR and subsequent annual updates. No patients developed HCC after SVR if the FIB-4 index decreased to <1.45. Conclusions The FIB-4 index retained its predictive ability for the risk of HCC when recalculated after SVR, despite the decrease in patients with high FIB-4 index values. Dynamic assessment of the FIB-4 index can be useful in the surveillance of HCC after SVR. Patients with a FIB-4 index <1.45 did not develop HCC even by the regression from advanced fibrosis after SVR. Further studies will be necessary to confirm these findings, which may result in a decrease in the number of patients in whom surveillance is required.

A genetic risk score predicts de novo hepatocellular carcinoma in hepatitis C cirrotic patients treated with direct-acting antivirals

2020 ◽  
Vol 73 ◽  
pp. S208-S209
Author(s):  
Elisabetta Degasperi ◽  
Enrico Galmozzi ◽  
Serena Pelusi ◽  
Roberta D’ambrosio ◽  
Roberta Soffredini ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C ◽  
Risk Score ◽  
Genetic Risk ◽  
De Novo ◽  
Genetic Risk Score ◽  
Direct Acting Antivirals ◽  
Direct Acting ◽  
De Novo Hepatocellular Carcinoma
Sign in / Sign up

Export Citation Format

Share Document